Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

2428 - Radiotherapy Alone for Human Papillomavirus-Related Locally Advanced Oropharyngeal Squamous Cell Carcinoma: a Single-Arm, Phase 2 Study

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Tumour Site

Head and Neck Cancers

Presenters

Norihiko Takemoto

Citation

Annals of Oncology (2018) 29 (suppl_8): viii372-viii399. 10.1093/annonc/mdy287

Authors

N. Takemoto1, M. Suzuki1, Y. Seo2, K. Ogawa2, H. Inohara1

Author affiliations

  • 1 Otorhinolaryngology-head And Neck Surgery, Osaka University Graduate School of Medicine, 565-0871 - Osaka/JP
  • 2 Radiation oncology, Osaka University Graduate School of Medicine, 565-0871 - Osaka/JP

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2428

Background

Oropharyngeal squamous cell carcinoma (OPSCC) is divided into two entities: human papillomavirus-related (HPV-related) and HPV-unrelated. Although it is established that patients with HPV-related locally advanced OPSCC (LA-OPSCC) survive significantly better than those with HPV-unrelated LA-OPSCC when treated with chemoradiotherapy (CRT), CRT remains the standard treatment for HPV-related LA-OPSCC. Given the young generation being more prone to be affected by HPV-related OPSCC, patients suffer from severe late toxicity associated with CRT for a long time. The hypothesis has emerged that patients with HPV-related LA-OPCC could be well managed by de-intensified treatment, resulting in long-term less morbidity without compromising survival. A series of clinical trials are in progress to certify this hypothesis.

Methods

We did a single-arm, phase 2 trial, enrolling patients with newly diagnosed, biopsy-proven, stage III or IV (excluding T4 and/or N3) OPSCC, positive for both p16 and HPV DNA. Patients received intensity-modulated radiotherapy alone for 70 Gy in 35 fractions. The primary endpoint was response at 11th week after treatment, assessed on RECIST and PERCIST.

Results

Between August 2013 and November 2016, 39 patients were enrolled with a median age of 64 years (range, 49-83). The majority of patients (24, 62%) had ≥10 pack-years smoking history. 35 (90%) patients showed complete response on RECISIT and/or complete metabolic response on PERCIST. One patient had regional recurrence, and two had distant metastasis. The 2-year overall survival rate and progression-free survival rate was 96% and 91% (95% CI, 76-99 and 75-97), respectively. During treatment 10 patients had grade 3 adverse events, but no grade 4 events were reported. 7 patients had gastrostomy tube placed during treatment, but no patient was dependent on gastrostomy tube at 4 weeks after treatment.

Conclusions

Radiotherapy alone was associated with high disease control and an improved toxicity profile. Radiotherapy alone has the potential to replace CRT as the standard treatment for HPV-related LA-OPSCC.

Clinical trial identification

UMIN000008953; Release date: 09/20/2012.

Legal entity responsible for the study

Osaka University.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.